Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Primary objective: To evaluate the effect of 12 weeks of subcutaneous (SC) AMG 145 monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in subjects with a 10-year Framingham risk score of 10% or less.
Critère d'inclusion
- Dyslipidemia